ABSTRACT
Gestational trophoblastic disease (GTD) develops from abnormal cellular proliferation of trophoblasts following fertilization. It includes benign trophoblastic disease (hydatidiform moles (HM)) and the malignant trophoblastic diseases or gestational trophoblastic neoplasia (GTN). The frequency of the GTD in Tunisia is one per 918 deliveries. The aim of this study is to analyze the clinical characteristics, treatment and outcomes of GTD at Salah Azaiez Institute (ISA). Medical records of women diagnosed with GTD at ISA from January 1st, 1981 to December 31st, 2012 were retrospectively reviewed. FIGO score was determined retrospectively for patients treated before 2002. One hundred and nine patients with GTN were included. Patients presented with metastases at 43% of cases. The most common metastatic sites were lung (30%) and vagina (13%). Fifty six (56 (51%) patients had low-risk and 21 (19%) cases had high-risk, the FIGO score was not assessed in 32 cases. After a median follow-up of 46 months, 21 patients were lost to follow-up, 12 patients died, 19 progressed and 8 relapsed. At 10 years, the OS rate was 85% and the PFS rate 79%. OS was significantly influenced by the presence of metastases at presentation (M0 100 % vs. Metastatic 62 %; p < 0.0001), FIGO stage (I-II 100% VS 61% and 65% for stage III and IV; p < 0.001), FIGO score (low-risk 99 % vs. high-risk 78 %; p < 0.001). GTN is a significant source of maternal morbidity with increased risk of mortality from complications if not detected early and treated promptly.
Subject(s)
Gestational Trophoblastic Disease/epidemiology , Hydatidiform Mole/epidemiology , Adolescent , Adult , Female , Follow-Up Studies , Gestational Trophoblastic Disease/pathology , Gestational Trophoblastic Disease/therapy , Humans , Hydatidiform Mole/pathology , Hydatidiform Mole/therapy , Lung Neoplasms/epidemiology , Lung Neoplasms/secondary , Middle Aged , Neoplasm Staging , Pregnancy , Progression-Free Survival , Retrospective Studies , Survival Rate , Tunisia , Vaginal Neoplasms/epidemiology , Vaginal Neoplasms/secondary , Young AdultABSTRACT
Breast cancer is the first cancer in women worldwide. Since the previous estimates of WHO in 2008, incidence is increasing and it is estimated that 30% of women will develop immediately a metastatic form. However, advances in molecular biology and the discovery of new therapies have extended significantly the survival of patients and improved the quality of life of patients with metastatic breast cancer. The study of gene expression and protein profile has resulted in a finer classification of breast cancer and adapt the treatment of patients according to their molecular profiles. The purpose of our work is to describe the different targeted therapies used in the MBC and their action's mechanism referring to various therapeutic trials described in the literature.
Subject(s)
Breast Neoplasms/pathology , Breast Neoplasms/therapy , Molecular Targeted Therapy/methods , Antineoplastic Agents, Immunological/therapeutic use , Clinical Trials as Topic/statistics & numerical data , Female , Humans , Immunotherapy/methods , Immunotherapy/trends , Molecular Targeted Therapy/trends , Neoplasm Metastasis , Precision Medicine/methods , Precision Medicine/trends , Protein Kinase Inhibitors/therapeutic useABSTRACT
Primary lung lymphomas are rare tumors representing less than 1% of malignant tumors of the lung. The most frequent form is the mucosa-associated lymphoid tissue (MALT). Ocular involvement is also rare and it is mostly located in the lachrymal glands. We report the case of a patient with pulmonary MALT lymphoma associated with synchronous involvement of the lachrymal glands. This study illustrates the nonspecific clinical, radiological and evolutionary features of this disease.
Subject(s)
Eye Neoplasms/diagnosis , Lacrimal Apparatus Diseases/diagnosis , Lung Neoplasms/diagnosis , Lymphoma, B-Cell, Marginal Zone/diagnosis , Aged , Eye Neoplasms/pathology , Humans , Lacrimal Apparatus Diseases/pathology , Lung Neoplasms/pathology , Lymphoma, B-Cell, Marginal Zone/pathology , Male , Neoplasms, Multiple PrimaryABSTRACT
BACKGROUND: Adult granulosa cell tumors (AGCTs) are the most common sex cord-stromal tumors. Unlike epithelial ovarian tumors, they occur in young women and are usually detected at an early stage. The aim of this study was to report the clinical and pathological characteristics of AGCT patients and to identify the prognostic factors. METHODS: All cases of AGCTs, treated at Salah Azaïz Institute between 1995 and 2010, were retrospectively included. Kaplan-Meier's statistical method was used to assess the relapse-free survival and the overall survival. RESULTS: The final cohort included 31 patients with AGCT. The mean age was 53 years (35-73 years). Patients mainly presented with abdominal mass and/or pain (61%, n = 19). Mean tumor size was 20 cm. The majority of patients had a stage I disease (61%, n = 19). Two among 3 patients with stage IV disease had liver metastasis. Mitotic index was low in 45% of cases (n = 14). Surgical treatment was optimal in almost all cases (90%, n = 28). The median follow-up time was 14 years (1-184 months). Ten patients relapsed (32%) with a median RFS of 8.4 years (6.8-9.9 years). Mean overall survival was 13 years (11-15 years). Stage I disease and low-to-intermediate mitotic index were associated with a better prognosis in univariate analysis (resp., p = 0.05 and p = 0.02) but were not independent prognostic factors. CONCLUSION: GCTs have a long natural history with common late relapses. Hence, long active follow-up is recommended. In Tunisian patients, hepatic metastases were more frequent than occidental series. The prognosis remains good and initial staging at diagnosis is an important prognostic factor.
